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We read with great interest the paper by Villa et al (2001) on
megestrol treatment of inoperable HCC. Having been involved in
hormonal treatment of HCC since the 80ie (Farinati et al, 1990)
and knowing that, despite all efforts, there is no effective treatment
at present for a patient with advanced disease (Simonetti et al,
1997), any good news on a new treatment is eagerly awaited. With
this in mind, and based on previously published papers (Chao et al,
1997) and on personal communications by Professor Villa, we also
started in 1999 an open label, uncontrolled prospective trial of
megestrol in the treatment of HCC patients. At least at that time
performing a second biopsy to test the type of oestrogen receptor
present was hardly conceivable and the discussion on whether or
not a biopsy is mandatory (and ethical) in patients with cirrhosis
and a liver lesion confirmed by both US and CT scanning and by
alfafetoprotein levels higher than 200–400 ng/ml was open, as it is
now. We therefore decided to enroll all the consecutive patients
diagnosed in our unit as having HCC on the bases of either a
confirmatory biopsy or a compatible CT scanning and signifi-
cantly increased alfafetoprotein levels, without testing for
oestrogen receptor. To be able to judge on biohumoral and onco-
logical response rate, only patients in whom alfafetoprotein levels
had been assessed and were higher that the cut-off (14 ng/ml) and
hepatic masses were clearly measurable by US scanning were
selected. On these premises, we enrolled 37 consecutive patients
(28 males, 9 females, mean age 67.8, range 56–79) with HCC in
cirrhosis (23 HCV-related, 5 HBV-related, 7 in alcoholic cirrhosis,
2 with mixed [HCV+HBV] etiology). No patient was eligible for
OLTx, surgery, percutaneous locoregional treatments (PEI or
RFA), arterial lipiodol-mediated chemoembolization on the basis
of the tumour burden, the presence of neoplastic portal thrombosis
or their Child-Pugh status (Child-Pugh A = 21, B = 15, C = 1). We
decided to administer megestrol (160 mg daily) for at least 60
days, before reassessing the patients’ conditions. The drug was
withdrawn in case of clear disease progression, patients’ death or
appearance of serious adverse events clearly correlated with mege-
strol administration. The mean time of administration was 4.6
months (range 7–395 days). Oncological and biohumoral (alfafe-
toprotein levels) response rate were assessed together with
patients’ performance status (Karnowski index). 
In one patient treatment was suspended after 1 week because of
hospital admission due to development of ascites. Adverse events
were observed in 16 patients: 5 ascites, 5 fever, 3 portal throm-
bosis, 5 itching, 3 bleeding episodes (2 from oesophageal varices
and 1 from duodenal ulcer), 5 appearance or worsening of weak-
ness, 1 deep venous thrombosis. The relation of these episodes to
megestrol treatment was judged as possible in the large majority of
cases and probable with respect to deep venous thrombosis,
described during megestrol treatment (Force et al, 1999) and
duodenal ulcer bleeding, also reported in the literature (Colleoni
et al, 1995). As of 1 May 2001 26 patients are dead and 10 survive,
mean survival being 7 months, with a range of 2 to 19 months and
a 19% 1-year survival. Overall, one partial response was observed
in a female HCC patient with HCV-related cirrhosis (Child A) in
whom tumour mass decreased by more than 50%, with a drop of
alfafetoprotein levels from 110 ng/dl to 18 ng/dl and with weight
gain of 23 kilograms, accompanied by appetite increase, hair
growth and psycological improvement (Figure 1). In this patient
megestrol was first reduced for development of obesity and then
withdrawn for admission due to bleeding from duodenal ulcer (see
Figure 1). After suspension and then despite readministration, alfafe-
toprotein increased and an additional nodule appeared at US scan-
ning. In two other patients a biohumoral response was observed with
reduction of alfafetoprotein levels from 1256 ng/dl to 22 ng/dl in the
first patient, who had a stable disease from the oncological point of
view, and from 2090 ng/dl to 1044 ng/dl in a second patient with,
however, disease progression at US. Overall, mean alfafetoprotein
levels went from 2640+/-2218 ng/dl to 3093+/–4120 ng/dl at the
end of treatment, with a 17% increase. Additionally, 7 out of the
37 patients experienced a slight amelioration of their performance
status (Karnowski score from 70 to 80 as a mean). In all the
remaining patients (28/37) progressive disease was observed, with
no improvement in performance status. 
This prospective study is based on a pragmatic approach,
which is in any case much closer to the real clinical practice, since
very few centres will have the possibility to test liver biopsies
from HCC patients for the presence of wild-type or mutated
oestrogen receptor, in a situation in which the recent EASL guide-
lines state that a liver biopsy in a patient with suspected HCC is
necessary only in case of lesions of less than 2 cm or in doubtful
situations. The results obtained confirm that megestrol can, in
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some instances, favourably influence the course of the disease,
but that this, in a consecutive series of HCC patients, happens in a
small minority of cases, the treatment being purely palliative in a
relatively larger sub-group and of no use in the majority. This,
since the variant receptor is to be detected in HbsAg positive
patients (Villa et al, 1998), may well have something to do with
the fact that we, by now, see mostly patients with HCV-related
chronic liver damage and HCC. On the other hand, in four
patients development of portal or deep venous thrombosis was
observed, which could be considered an expected worsening in
patients with HCC, with respect to portal thrombosis, but that
could have something to do with the pro-coagulant properties of
megestrol at least in the case of deep venous damage (Force et al,
1999). Our experience therefore, albeit limited and uncontrolled,
suggests that side effects, particularly on blood coagulation, may
not be irrelevant. 
In summary, our feeling is that megestrol and the variant
oestrogen receptor may be more a step in the understanding of
the patho-physiological mechanisms underlying HCC develop-
ment and progression than a true advance in HCC treatment but
we are available to change our mind if new additional data will
confirm those reported by Villa et al (2001) and deny our find-
ings. This is also because the tamoxifen story has taught
everyone, and us more than others, that preliminary, successful
small size trials are to be confirmed by large size prospective
randomized placebo-controlled studies before a drug enters
routine clinical practice. 
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Reply
Sir, 
Dr Farinati and colleagues have reported an uncontrolled experi-
ence with megestrol in the treatment of inoperable hepatocellular
carcinoma. Their results were somewhat different from those we
have reported in Br J Cancer (Villa et al, 2001) and we would like
to add some considerations. 
Despite the fact that megestrol has a rationale in HCC charac-
terised by both wild-type and variant oestrogen receptors (vERs),
as its action is displayed at post-receptorial level (and therefore
able to interfere both vERs and wild-type ERs (wtERs), still the
natural history of HCC with wtERs is so favourable and the
growth speed of the tumours so slow that megestrol or any other
antihormonal drug, would not add much in terms of amelioration
of prognosis (Villa et al, 2000). The choice of treating with mege-
strol only patients with vERs was therefore justified by the much
more aggressive clinical course of these HCCs, which could allow
easier identification of any effect on tumour growth or an improve-
ment in survival. As variant ERs are usually not more than 30% of
patients with HCC, the higher percentage of patients with wild-
type ERs could obscure a favourable effect of megestrol when this
treatment is used in a mixed population. 
Furthermore, the uncontrolled design of the study by Farinati
et al, could not allow perception of the most relevant finding of our
study, i.e. the improvement in survival in treated patients. It was,
in fact, already evident from our data that megestrol did not deter-
mine regression of tumour mass (except in a few cases) whereas
slowing down of tumour growth was remarkable in comparison
with untreated patients. This effect was short-lived but sufficient
to determine a significant improvement of survival at 1 year (Villa
et al, 2001). Certainly, megestrol was not powerful enough to cure
HCC, but in these patients with ominous prognosis, a gain of
10–12 months in survival can be considered an achievement. In a
few of them, clinical improvement was also accompanied by
significant regression of tumour mass which allowed performance
of radical treatment (E Villa and V Mazzaferro, personal commu-
nication). 
Last but not least, the side effects reported by Farinati et al (e.g.
portal vein thrombosis, deep vein thrombosis, bleeding etc.) may
also spontaneously occur in HCC patients: again the uncontrolled
experimental design by Farinati was certainly not suitable for
correctly allocating side effects to therapy or to disease. Indeed,
in our series increase in appetite and in weight occurred in a
remarkable percentage of treated patients and in none of the
control. However, as for the vascular complications, deep vein
thrombosis occurred in the same proportion in treated and
untreated patients. 
In conclusion, these considerations underline the need to
observe very strict methodological rules when performing thera-
peutic trials: only a controlled method allows identification and
correct allocation of both benefits and side effects. 
E Villa, N De Maria, A Colantoni, 
M Manno and H Bertani 
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